|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Vickers AJ: Prostate cancer screening:
Time to question how to optimize the ratio of benefits and harms.
Ann Intern Med. 167:509–510. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Alarcón-Zendejas AP, Scavuzzo A,
Jiménez-Ríos MA, Álvarez-Gómez RM, Montiel-Manríquez R,
Castro-Hernández C, Jiménez-Dávila MA, Pérez-Montiel D,
González-Barrios R, Jiménez-Trejo F, et al: The promising role of
new molecular biomarkers in prostate cancer: From coding and
non-coding genes to artificial intelligence approaches. Prostate
Cancer Prostatic Dis. 25:431–443. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fenton JJ, Weyrich MS, Durbin S, Liu Y,
Bang H and Melnikow J: Prostate-Specific Antigen-Based screening
for prostate cancer: Evidence report and systematic review for the
US preventive services task force. JAMA. 319:1914–1931.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
US Preventive Services Task Force.
Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB,
Davidson KW, Doubeni CA, Ebell M, Epling JW Jr, et al: Screening
for prostate cancer: US preventive services task force
recommendation statement. JAMA. 319:1901–1913. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gudmundsson J, Sigurdsson JK,
Stefansdottir L, Agnarsson BA, Isaksson HJ, Stefansson OA,
Gudjonsson SA, Gudbjartsson DF, Masson G, Frigge ML, et al:
Genome-wide associations for benign prostatic hyperplasia reveal a
genetic correlation with serum levels of PSA. Nat Commun.
9(4568)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhao Y, Zhang Y, Wang X, Lin D and Chen Z:
Relationship between body mass index and concentrations of prostate
specific antigen: A cross-sectional study. Scand J Clin Lab Invest.
80:162–167. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Liu Y, Xiao G, Zhou JW, Yang JK, Lu L,
Bian J, Zhong L, Wei QZ, Zhou QZ, Xue KY, et al: Optimal starting
age and baseline level for repeat tests: Economic concerns of PSA
screening for Chinese Men-10-Year experience of a single center.
Urol Int. 104:230–238. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tan GH, Nason G, Ajib K, Woon DTS,
Herrera-Caceres J, Alhunaidi O and Perlis N: Smarter screening for
prostate cancer. World J Urol. 37:991–999. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Misra-Hebert AD, Hu B, Klein EA,
Stephenson A, Taksler GB, Kattan MW and Rothberg MB: Prostate
cancer screening practices in a large, integrated health system:
2007-2014. BJU Int. 120:257–264. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cortellini A, Ricciuti B, Borghaei H,
Naqash AR, D'Alessio A, Fulgenzi CAM, Addeo A, Banna GL and Pinato
DJ: Differential prognostic effect of systemic inflammation in
patients with non-small cell lung cancer treated with immunotherapy
or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cancer. 128:3067–3079. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cao Y, Zheng X, Hu Y, Li J, Huang B, Zhao
N, Liu T, Cai K and Tian S: Levels of systemic inflammation
response index are correlated with tumor-associated bacteria in
colorectal cancer. Cell Death Dis. 14(69)2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Song M, Zhang Q, Song C, Liu T, Zhang X,
Ruan G, Tang M, Xie H, Zhang H, Ge Y, et al: The advanced lung
cancer inflammation index is the optimal inflammatory biomarker of
overall survival in patients with lung cancer. J Cachexia
Sarcopenia Muscle. 13:2504–2514. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cui S, Cao S, Chen Q, He Q and Lang R:
Preoperative systemic inflammatory response index predicts the
prognosis of patients with hepatocellular carcinoma after liver
transplantation. Front Immunol. 14(1118053)2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sawada R, Akiyoshi T, Kitagawa Y, Hiyoshi
Y, Mukai T, Nagasaki T, Yamaguchi T, Konishi T, Yamamoto N, Ueno M
and Fukunaga Y: Systemic inflammatory markers combined with
tumor-infiltrating lymphocyte density for the improved prediction
of response to neoadjuvant chemoradiotherapy in rectal cancer. Ann
Surg Oncol. 28:6189–6198. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sun Z, Ju Y, Han F, Sun X and Wang F:
Clinical implications of pretreatment inflammatory biomarkers as
independent prognostic indicators in prostate cancer. J Clin Lab
Anal. 32(e22277)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yuksel OH, Urkmez A, Akan S, Yldirim C and
Verit A: Predictive value of the platelet-To-Lymphocyte ratio in
diagnosis of prostate cancer. Asian Pac J Cancer Prev.
16:6407–6412. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lee JW, Jeong H, Son H and Cho MC:
Platelet-to-lymphocyte ratio is not a predictor of clinically
significant prostate cancer at the prostate biopsy: A large cohort
study. Sci Rep. 11(14240)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wei C, Tian L, Jia B, Wang M, Xiong M, Hu
B, Deng C, Hou Y, Hou T, Yang X and Chen Z: Association between
serum triglycerides and prostate specific antigen (PSA) among U.S.
Males: National Health and Nutrition Examination Survey (NHANES),
2003-2010. Nutrients. 14(1325)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liu Z, Chen C, Yu F, Yuan D, Wang W, Jiao
K, Yang S, Zhang Y, Wang Y, Liu L, et al: Association of total
dietary intake of sugars with Prostate-Specific antigen (PSA)
concentrations: Evidence from the National Health and Nutrition
Examination Survey (NHANES), 2003-2010. Biomed Res Int.
2021(4140767)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
McDonald AC, Vira MA, Vidal AC, Gan W,
Freedland SJ and Taioli E: Association between systemic
inflammatory markers and serum prostate-specific antigen in men
without prostatic disease-the 2001-2008 National Health and
Nutrition Examination Survey. Prostate. 74:561–567. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liao K, Zhang X, Liu J, Teng F, He Y,
Cheng J, Yang Q, Zhang W, Xie Y, Guo D, et al: The role of
platelets in the regulation of tumor growth and metastasis: The
mechanisms and targeted therapy. MedComm (2020).
4(e350)2023.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Wang J, Zhou X, He Y, Chen X, Liu N, Ding
Z and Li J: Prognostic role of platelet to lymphocyte ratio in
prostate cancer: A meta-analysis. Medicine (Baltimore).
97(e12504)2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li Y, Wang H, Zhao Z, Yang Y, Meng Z and
Qin L: Effects of the interactions between platelets with other
cells in tumor growth and progression. Front Immunol.
14(1165989)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tao DL, Tassi Yunga S, Williams CD and
McCarty OJT: Aspirin and antiplatelet treatments in cancer. Blood.
137:3201–3211. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li L, Yu R, Cai T, Chen Z, Lan M, Zou T,
Wang B, Wang Q, Zhao Y and Cai Y: Effects of immune cells and
cytokines on inflammation and immunosuppression in the tumor
microenvironment. Int Immunopharmacol. 88(106939)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Huang SH, Waldron JN, Milosevic M, Shen X,
Ringash J, Su J, Tong L, Perez-Ordonez B, Weinreb I, Bayley AJ, et
al: Prognostic value of pretreatment circulating neutrophils,
monocytes, and lymphocytes in oropharyngeal cancer stratified by
human papillomavirus status. Cancer. 121:545–555. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sznurkowski JJ, Zawrocki A, Emerich J and
Biernat W: Prognostic significance of CD4+ and CD8+ T cell
infiltration within cancer cell nests in vulvar squamous cell
carcinoma. Int J Gynecol Cancer. 21:717–721. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ropponen KM, Eskelinen MJ, Lipponen PK,
Alhava E and Kosma VM: Prognostic value of tumour-infiltrating
lymphocytes (TILs) in colorectal cancer. J Pathol. 182:318–324.
1997.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes in
triple-negative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Schuettfort VM, D'Andrea D, Quhal F,
Mostafaei H, Laukhtina E, Mori K, König F, Rink M, Abufaraj M,
Karakiewicz PI, et al: A panel of systemic inflammatory response
biomarkers for outcome prediction in patients treated with radical
cystectomy for urothelial carcinoma. BJU Int. 129:182–193.
2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Xie H, Ruan G, Wei L, Deng L, Zhang Q, Ge
Y, Song M, Zhang X, Lin S, Liu X, et al: The inflammatory burden
index is a superior systemic inflammation biomarker for the
prognosis of non-small cell lung cancer. J Cachexia Sarcopenia
Muscle. 14:869–878. 2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Shafique K, Proctor MJ, McMillan DC,
Qureshi K, Leung H and Morrison DS: Systemic inflammation and
survival of patients with prostate cancer: Evidence from the
Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis.
15:195–201. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Jang WS, Cho KS, Kim MS, Yoon CY, Kang DH,
Kang YJ, Jeong WS, Ham WS and Choi YD: The prognostic significance
of postoperative neutrophil-to-lymphocyte ratio after radical
prostatectomy for localized prostate cancer. Oncotarget.
8:11778–11787. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kwon YS, Han CS, Yu JW, Kim S, Modi P,
Davis R, Park JH, Lee P, Ha YS, Kim WJ and Kim IY: Neutrophil and
lymphocyte counts as clinical markers for stratifying low-risk
prostate cancer. Clin Genitourin Cancer. 14:e1–e8. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wang S, Ji Y, Chen Y, Du P, Cao Y, Yang X,
Ma J, Yu Z and Yang Y: The values of systemic Immune-Inflammation
index and Neutrophil-Lymphocyte ratio in the localized prostate
cancer and benign prostate hyperplasia: A retrospective clinical
study. Front Oncol. 11(812319)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wang Y, Xu F, Pan J, Zhu Y, Shao X, Sha J,
Wang Z, Cai Y, Liu Q, Dong B, et al: Platelet to lymphocyte ratio
as an independent prognostic indicator for prostate cancer patients
receiving androgen deprivation therapy. BMC Cancer.
16(329)2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li F, Hu H, Gu S, Chen X and Sun Q:
Platelet to lymphocyte ratio plays an important role in prostate
cancer's diagnosis and prognosis. Int J Clin Exp Med.
8:11746–11751. 2015.PubMed/NCBI
|
|
39
|
Chong W, Zhang Z, Luo R, Gu J, Lin J, Wei
Q, Li B, Myers R, Lu-Yao G, Kelly WK, et al: Integration of
circulating tumor cell and neutrophil-lymphocyte ratio to identify
high-risk metastatic castration-resistant prostate cancer patients.
BMC Cancer. 21(655)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Bauckneht M, Rebuzzi SE, Signori A,
Frantellizzi V, Murianni V, Lodi Rizzini E, Lavelli V, Donegani MI,
Ponzano M, Gaudiano A, et al: The prognostic power of inflammatory
indices and clinical factors in metastatic castration-resistant
prostate cancer patients treated with radium-223 (BIO-Ra study).
Eur J Nucl Med Mol Imaging. 49:1063–1074. 2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Langsenlehner T, Pichler M, Thurner EM,
Krenn-Pilko S, Stojakovic T, Gerger A and Langsenlehner U:
Evaluation of the platelet-to-lymphocyte ratio as a prognostic
indicator in a European cohort of patients with prostate cancer
treated with radiotherapy. Urol Oncol.
33(201.e9-e16)2015.PubMed/NCBI View Article : Google Scholar
|
